Lentiviral vectors are beginning to emerge as a viable choice for human gene therapy. Here, we describe a method that combines the convenience of a suspension cell line with a scalable, nonchemically based, and GMP-compliant transfection technique known as flow electroporation (EP). Flow EP parameters for serum-free adapted HEK293FT cells were optimized to limit toxicity and maximize titers. Using a third generation, HIV-based, lentiviral vector system pseudotyped with the vesicular stomatitis glycoprotein envelope, both small- and large-volume transfections produced titers over 1×108 infectious units/mL. Therefore, an excellent option for implementing large-scale, clinical lentiviral productions is flow EP of suspension cell lines.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., CattaneoF., GalimbertiS.et al.2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med., 360:447–458.
2.
AnsorgeS., LanthierS., TransfiguracionJ.et al.2009. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene Med., 11:868–876.
3.
BajgelmanM.C., Costanzi-StraussE., StraussB.E.2003. Exploration of critical parameters for transient retrovirus production. J. Biotechnol., 103:97–106.
4.
BroussauS., JabbourN., LachapelleG.et al.2008. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther., 16:500–507.
5.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 467:318–322.
6.
CockrellA.S., MaH., FuK.et al.2006. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther., 14:276–284.
7.
CoteJ., GarnierA., MassieB., KamenA.1998. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol. Bioeng., 59:567–575.
8.
FarsonD., WittR., McGuinnessR.et al.2001. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther., 12:981–997.
9.
FelgnerP.L., GadekT.R., HolmM.et al.1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A., 84:7413–7417.
GrahamF.L., van der EbA.J.1973. Transformation of rat cells by DNA of human adenovirus 5. Virology, 54:536–539.
12.
GrahamF.L., SmileyJ., RussellW.C., NairnR.1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36:59–74.
KafriT., van PraagH., OuyangL.et al.1999. A packaging cell line for lentivirus vectors. J. Virol., 73:576–584.
15.
KahlC.A., MarshJ., FyffeJ.et al.2004. Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J. Virol., 78:1421–1430.
16.
KarolewskiB.A., WatsonD.J., ParenteM.K., WolfeJ.H.2003. Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum. Gene Ther., 14:1287–1296.
17.
KlagesN., ZuffereyR., TronoD.2000. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther., 2:170–176.
18.
KuateS., WagnerR., UberlaK.2002. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J. Gene Med., 4:347–355.
19.
KubiniecR.T., LiangH., HuiS.W.1990. Effects of pulse length and pulse strength on transfection by electroporation. Biotechniques, 8:16–20.
20.
KumarM., BradowB.P., ZimmerbergJ.2003. Large-scale production of pseudotyped lentiviral vectors using baculovirus GP64. Hum. Gene Ther., 14:67–77.
21.
KurodaH., KutnerR.H., BazanN.G., ReiserJ.2009. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J. Virol. Methods, 157:113–121.
22.
KutnerR.H., ZhangX.Y., ReiserJ.2009. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc., 4:495–505.
23.
Le RuA., JacobD., TransfiguracionJ.et al.2010. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine, 28:3661–3671.
24.
LeschH.P., LaitinenA., PeixotoC.et al.2011. Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors. Gene Ther., 18:531–538
25.
LevineB.L., HumeauL.M., BoyerJ.et al.2006. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U. S. A., 103:17372–17377.
26.
LiL., LiuL.N., AllenC.et al.2008. DNase treatment following electrotransfection enhances cell viability and transgene expression. Mol. Ther., 16:S315.
27.
LiL., LiuL.N., FellerS.et al.2010. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther., 17:147–154.
28.
LiL.H., ShivakumarR., FellerS.et al.2002. Highly efficient, large volume flow electroporation. Technol. Cancer Res. Treat., 1:341–350.
MochizukiH., SchwartzJ.P., TanakaK.et al.1998. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J. Virol., 72:8873–8883.
31.
MontiniE., CesanaD., SchmidtM.et al.2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest., 119:964–975.
32.
NiY., SunS., OparaochaI.et al.2005. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med., 7:818–834.
33.
PacchiaA.L., AdelsonM.E., KaulM.et al.2001. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology, 282:77–86.
34.
PhezE., FaurieC., GolzioM.et al.2005. New insights in the visualization of membrane permeabilization and DNA/membrane interaction of cells submitted to electric pulses. Biochim. Biophys. Acta, 1724:248–254.
35.
RolsM.P.2006. Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim. Biophys. Acta, 1758:423–428.
36.
RolsM.P., TeissieJ.1998. Electropermeabilization of mammalian cells to macromolecules: control by pulse duration. Biophys. J., 75:1415–1423.
37.
RolsM.P., CouletD., TeissieJ.1992. Highly efficient transfection of mammalian cells by electric field pulses. Application to large volumes of cell culture by using a flow system. Eur. J. Biochem, 206:115–121.
38.
SastryL., XuY., CooperR.et al.2004. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum. Gene Ther., 15:221–226.
39.
SeguraM.M., GarnierA., DurocherY.et al.2007. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng., 98:789–799.
40.
SeguraM.M., GarnierA., DurocherY.et al.2010. New protocol for lentiviral vector mass production. Methods Mol. Biol., 614:39–52.
41.
Sena-EstevesM., TebbetsJ.C., SteffensS.et al.2004. Optimized large-scale production of high titer lentivirus vector pseudotypes. J. Virol. Methods, 122:131–139.
42.
SlepushkinV., ChangN., CohenR.et al.2003. Large-scale purification of a lentiviral vector by size exclusion chromatography or Mustang Q ion exchange capsule. Bioproc. J., September/October89–95.
43.
SparacioS., PfeifferT., SchaalH., BoschV.2001. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther., 3:602–612.
44.
TransfiguracionJ., JaaloukD.E., GhaniK.et al.2003. Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum. Gene Ther., 14:1139–1153.
45.
TsongT.Y.1991. Electroporation of cell membranes. Biophys. J., 60:297–306.
46.
XuK., MaH., McCownT.J.et al.2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther., 3:97–104.
47.
ZuffereyR., DullT., MandelR.J.et al.1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol., 72:9873–9880.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
